Rigel Pharmaceuticals, Inc. (RIGL)

Market Cap	331.79M
Revenue (ttm)	179.28M
Net Income (ttm)	17.49M
Shares Out	17.87M
EPS (ttm)	0.99
PE Ratio	18.76
Forward PE	16.04
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,162
Open	18.56
Previous Close	18.16
Day's Range	18.56 - 18.57
52-Week Range	7.48 - 29.82
Beta	1.32
Analysts	Buy
Price Target	36.80 (+98.17%)
Earnings Date	May 6, 2025

About RIGL

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 29, 2000
• Employees: 164
• Stock Exchange: NASDAQ
• Ticker Symbol: RIGL
• Website: https://www.rigel.com

Analyst Forecast

According to 5 analysts, the average rating for RIGL stock is "Buy." The 12-month stock price forecast is $36.8, which is an increase of 98.17% from the latest price.

Price Target

$36.8

(98.17% upside)

Analyst Consensus: Buy